Vaxart (VXRT) Projected to Post Quarterly Earnings on Wednesday

Vaxart (NASDAQ:VXRT) is expected to be releasing its Q3 2025 results after the market closes on Wednesday, November 12th. Analysts expect Vaxart to post earnings of ($0.07) per share and revenue of $40.10 million for the quarter. Interested persons may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, November 13, 2025 at 4:30 PM ET.

Vaxart Price Performance

Shares of VXRT stock opened at $0.41 on Monday. Vaxart has a 1-year low of $0.26 and a 1-year high of $0.98. The company has a market cap of $93.19 million, a price-to-earnings ratio of -1.51 and a beta of 1.32. The stock has a 50 day simple moving average of $0.36 and a 200-day simple moving average of $0.41.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Goldman Sachs Group Inc. purchased a new stake in Vaxart during the 1st quarter worth approximately $31,000. Creative Planning purchased a new stake in shares of Vaxart during the second quarter worth approximately $33,000. Invesco Ltd. raised its stake in Vaxart by 93.1% in the 1st quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company’s stock valued at $60,000 after purchasing an additional 70,568 shares during the last quarter. Raymond James Financial Inc. lifted its holdings in Vaxart by 16.9% in the 2nd quarter. Raymond James Financial Inc. now owns 236,166 shares of the biotechnology company’s stock valued at $107,000 after purchasing an additional 34,075 shares in the last quarter. Finally, Jones Financial Companies Lllp boosted its stake in Vaxart by 276,364.7% during the 1st quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company’s stock worth $196,000 after purchasing an additional 478,111 shares during the last quarter. 18.05% of the stock is owned by hedge funds and other institutional investors.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.